- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07238023
Promoting Active Living Among People With Metastatic Breast Cancer
March 17, 2026 updated by: University of Oklahoma
Testing the Feasibility and Acceptability of a Remotely Delivered Program to Promote Active Living Among People With Metastatic Breast Cancer
Individuals with metastatic breast cancer are living longer but often face persistent fatigue, functional decline, and psychological distress.
Physical activity is generally safe for this population and may alleviate symptom burden.
Yet, limited interventions are tailored to the unique and needs and preferences of this population.
This study aims to evaluate the acceptability and feasibility of a mindfulness- and acceptance-based physical activity program designed to support mental, social, and spiritual well-being among people with metastatic breast cancer.
A single group, pretest-posttest trial (N=38) will be conducted to inform scalable strategies to promote active living and enhance quality of life among people with advanced cancer.
Study Overview
Status
Recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Estimated)
38
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Michael C Robertson, PhD, MPH
- Phone Number: 33145 14052718001
- Email: Michael-Robertson@ou.edu
Study Locations
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73104
- Recruiting
- TSET Health Promotion Research Center
-
Contact:
- Michael C Robertson, MPH, PhD
- Phone Number: 405-998-1451
- Email: alvy-lab@ou.edu
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
- having been diagnosed with metastatic breast cancer
- medical clearance from healthcare provider to participate in this study
- life expectancy of at least 6 months as per the participant's healthcare provider
- Eastern Cooperative Oncology Group performance status of or 0 or 1
- being willing and able to use a smartphone and web interface with or without assistance; if assistance is needed, it must be readily available
- adequate visual and hearing acuity to use a smartphone and web interface as indicated by self-report
- adequate motor capacity to use a smartphone and web interface as indicated by self-report
- willingness to download and use study-specific app(s), the Fitbit mobile application (this requires use of a Google Gmail account), and other mobile applications for study purposes as needed
- completed baseline survey
Exclusion Criteria:
- contraindications to physical activity (e.g., uncontrolled hypertension or cardiac disease noted by the patient's treating healthcare provider)
- presence of bone metastases deemed unstable by the treating healthcare provider.
- untreated brain metastases
- history of dementia or other major neurocognitive disorder
- received a diagnosed of Major Depressive Disorder within the previous 6 months
- received a diagnosis of a major psychiatric conditions such as bipolar disorder, psychosis, schizophrenia, or alcoholism that could affect the ability to understand and/or complete the study
- currently hospitalized
- enrolled in hospice
- inability to speak, read, and write in English at the 7th grade level
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Acceptance- and Mindfulness-Based Intervention
Provision of standard self-regulatory behavior change techniques, plus acceptance and mindfulness-based physical activity promotion
|
This intervention will be delivered over the course of up to 8-12 weeks. It will include:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Semi-structured Interviews
Time Frame: Week 9
|
Semi-structured interviews will be used to assess participants' overall experience and their perceptions of the usability, usefulness, and enjoyability of the intervention.
|
Week 9
|
|
Perceived ease of use
Time Frame: Week 9
|
Face valid questions will be used to determine whether participants found the interventions easy to use.
The face valid questions consists of five 7-point Likert-type items.
Responses range from "Not At All Easy" (scored as 1) to "Very Easy" (scored as 7).
Higher scores reflect greater ease of use.
|
Week 9
|
|
Perceived Usefulness
Time Frame: Week 9
|
Face valid questions will be used to determine whether participants found the interventions useful.
The face valid questions consists of five 7-point Likert-type items.
Responses range from "Not At All Useful" (scored as 1) to "Very Useful" (scored as 7).
Higher scores reflect greater perceived usefulness.
|
Week 9
|
|
Enjoyability - Face Valid Questions
Time Frame: Week 9
|
Face valid questions will be used to assess the enjoyability of the interventions in this study.
The face valid questions consists of five 7-point Likert-type items.
Responses range from "Not At All Enjoyable" (scored as 1) to "Very Enjoyable" (scored as 7).
Higher scores reflect greater enjoyability.
|
Week 9
|
|
Enjoyability - Interest/Enjoyment Subscale
Time Frame: Week 9
|
The interest/enjoyment subscale of the Intrinsic Motivation Inventory (IMIe) will be used to assess the enjoyability of the interventions in this study.
The IMIe sub-scale consists of seven 7-point Likert-type items.
Responses range from "Not At All True" (scored as 1) to "Very True" (scored as 7).
Higher scores reflect greater enjoyability.
|
Week 9
|
|
Feasibility of the Program - Study Retention
Time Frame: Week 9
|
We will assess program feasibility via measurements of study retention.
We will compute what percentage of enrolled participant complete post-intervention data collection procedures.
|
Week 9
|
|
Feasibility of the Program - Adherence
Time Frame: Week 9
|
We will assess program feasibility via measurements of intervention adherence.
We will compute what percentage of participants engage with at least 75% of the intervention modules.
|
Week 9
|
|
Feasibility of Collecting Biological Samples
Time Frame: Week 9
|
We will assess the feasibility of assessing gene expression in the present context by assessing what percentage of enrolled participants provide analyzable data in optional post-intervention blood draws.
|
Week 9
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Physical Activity
Time Frame: Baseline; Week 9
|
A modified Godin Leisure-Time Exercise Questionnaire will be used to assess participants' physical activity patterns.
This self-report measure assesses the number of minutes of strenuous-, moderate-, and light-intensity exercise in a typical week.
An additional item will be included that assesses the number of bouts of muscle-strengthening exercise in a typical week.
We will also gather data provided by consumer-grade, wearable physical activity trackers (Fitbit Charge series or similar).
|
Baseline; Week 9
|
|
Feelings of Vitality
Time Frame: Baseline; Week 9
|
The Subjective Vitality Scale (SVS) will be used to will be used to assess participants' feelings of vitality.
The SVS consists of seven 7-point Likert-type items.
Responses range from "Not At All True" (scored as 1) to "Very True" (scored as 7).
Higher scores reflect greater enjoyability.
|
Baseline; Week 9
|
|
Meaning Salience
Time Frame: Baseline; Week 9
|
The Meaning Awareness Scale (MAS) will be used to assess meaning salience.
The MAS consists of six 7-point Likert-type items.
Responses range from "Very Rarely" (scored as 1) to "Very Often" (scored as 7).
Higher scores reflect greater meaning salience.
|
Baseline; Week 9
|
|
Psychological Flexibility
Time Frame: Baseline; Week 9
|
The Personalized Psychological Flexibility Index (PPFI) will be used to assess psychological flexibility.
The PPFI consists of sixteen 7-point Likert-type items.
Responses range from "Strongly Disagree" (scored as 1) to "Strongly Agree" (scored as 7).
Higher scores reflect greater psychological flexibility.
|
Baseline; Week 9
|
|
Physical Activity Motivation
Time Frame: Baseline; Week 9
|
The Behavioral Regulation for Exercise Questionnaire-4 (BREQ-4) will be used to assess physical activity motivation.
The BREQ-4 consists of twenty-eight 5-point Likert-type items.
Responses range from "Not True For Me" (scored as 0) to "Very True For Me" (scored as 4).
It is best practice to score each of the seven subscales separately (i.e., obtain separate scores for amotivation, external regulation, introjected avoidance regulation, introjected approach regulation, identified regulation, integrated regulation, and intrinsic regulation).
For each subscale, higher scores reflect greater usage of that type of regulation.
|
Baseline; Week 9
|
|
Physical Activity Acceptance
Time Frame: Baseline; Week 9
|
The Physical Activity Acceptance Questionnaire (PAAQ) will be used to assess physical activity acceptance.
The PAAQ consists of ten 7-point Likert-type items.
Responses range from "Never True" (scored as 1) to "Always True" (scored as 7).
It is best practice to score each of the two subscales separately (i.e., obtain separate scores for cognitive acceptance and behavioral commitment).
For each subscale, higher scores reflect greater acceptance/commitment.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Physical Function
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The physical function subscale has 4 items with 5-point Likert-type responses (e.g., ranging from "Unable To Do" (scored as 1) to "Without Any Difficulty" (scored as 5).
Higher scores for physical function are favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Anxiety
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The anxiety subscale has 4 items with 5-point Likert-type responses (e.g., ranging from "Never" (scored as 1) to "Always" (scored as 5).
Higher scores for anxiety are not favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Depressive Symptoms
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The depressive symptoms subscale has 4 items with 5-point Likert-type responses (e.g., ranging from "Never" (scored as 1) to "Always" (scored as 5).
Higher scores for depressive symptoms are not favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Fatigue
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The fatigue subscale has 4 items with 5-point Likert-type responses (e.g., ranging from "Not At All" (scored as 1) to "Very Much" (scored as 5).
Higher scores for fatigue are not favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Sleep Disturbance
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The sleep disturbance subscale has 4 items with 5 point Likert-type responses (e.g., ranging from "Not At All" (scored as 1) to "Very Much" (scored as 5).
Higher scores indicate more sleep disturbance.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Ability to Participate in Social Roles and Activities
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The ability to participate in social roles and activities subscale has 4 items with 5 point Likert-type responses (e.g., ranging from "Not At All" (scored as 1) to "Very Much" (scored as 5).
Higher scores for ability to participate in social roles and activities are not favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Pain Interference
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The pain interference subscale has 4 items with 5 point Likert-type responses (e.g., ranging from "Not At All" (scored as 1) to "Very Much" (scored as 5).
Higher scores for pain interference are not favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Cognition
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The cognition subscale has 2 items with 5-point Likert-type responses (e.g., ranging from "Not At All" (scored as 1) to "Very Much" (scored as 5).
Higher scores for cognition are favorable.
|
Baseline; Week 9
|
|
Health-Related Quality of Life - Pain Intensity
Time Frame: Baseline; Week 9
|
The Patient-Reported Outcomes Measurement Information System-29 (PROMIS-29+2 Profile v2.1) will be used to assess health-related quality of life.
The PROMIS-29+2 Profile v2.1 consists of thirty-one items spanning nine subscales (i.e., physical function, anxiety, depressive symptoms, fatigue, sleep disturbance, ability to participate in social roles and activities, pain interference, cognition, and pain intensity).
The pain intensity subscale has 1 item with responses ranging from "No Pain" (scored as 0) to "Worst Pain Imaginable" (scored as 10).
Higher scores for pain intensity are not favorable.
|
Baseline; Week 9
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Michael C Robertson, MPH, PhD, University of Oklahoma
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 27, 2026
Primary Completion (Estimated)
June 1, 2026
Study Completion (Estimated)
June 1, 2026
Study Registration Dates
First Submitted
September 29, 2025
First Submitted That Met QC Criteria
November 14, 2025
First Posted (Actual)
November 20, 2025
Study Record Updates
Last Update Posted (Actual)
March 19, 2026
Last Update Submitted That Met QC Criteria
March 17, 2026
Last Verified
March 1, 2026
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 18941
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
UNDECIDED
IPD Plan Description
We are undecided about sharing individual participant data at this time.
This study involves a sensitive population and may result in a relatively small sample size, which increases the risk of participant re-identification even after de-identification procedures.
We will evaluate data sharing feasibility after study completion, taking into account participant privacy protections, ethical considerations, and institutional policies.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Metastatic Invasive Breast Cancer
-
Dana-Farber Cancer InstitutePfizerCompletedBreast Cancer Stage IV | Unresectable Locally Advanced Invasive Breast Cancer | Metastatic Invasive Breast CancerUnited States
-
Massachusetts General HospitalPuma Biotechnology, Inc.; Celcuity, Inc.WithdrawnMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer | Stage IV (Metastatic) Breast CancerUnited States
-
A Bapsi Chakravarthy, MDCompletedResistant Breast Cancer | Non-metastatic Invasive Breast CancerUnited States
-
Ana C Garrido-Castro, MDMerck Sharp & Dohme LLC; Gilead SciencesActive, not recruitingMetastatic Breast Cancer | Invasive Breast Cancer | HER2-negative Breast Cancer | HR-Positive Breast CancerUnited States
-
Sindh Institute of Urology and TransplantationCompletedBreast Cancer | Breast Neoplasms | Breast Cancer Metastatic | Breast Cancer Stage | Breast Cancer InvasivePakistan
-
Outcomes4MeMassachusetts General HospitalUnknownBreast Cancer | Metastatic Breast Cancer | Breast Carcinoma | Invasive Breast Cancer | Metastatic Breast CarcinomaUnited States
-
Abramson Cancer Center at Penn MedicineCompletedEstrogen-receptor Positive Invasive Metastatic Breast CancerUnited States
-
The Netherlands Cancer InstituteMaarten van de Weijden FoundationRecruitingOligoprogressive | Metastatic Cancer | Breast Cancer InvasiveNetherlands
-
Stanford UniversityCalifornia Breast Cancer Research ProgramCompletedDepression | Breast Cancer | Stress | Breast Cancer Non-invasive Breast Cancer | Breast Cancer Early Stage Breast Cancer (Stage 1-3) | Breast Cancer Metastatic Breast CancerUnited States
-
Sonya ReidSusan G. Komen Breast Cancer Foundation; AgendiaRecruitingMetastatic Breast Cancer | Invasive Mammary CarcinomaUnited States
Clinical Trials on Acceptance- and mindfulness-based physical activity promotion
-
University of California, San DiegoCompletedBreast CancerUnited States
-
Yale UniversityNational Cancer Institute (NCI)Completed
-
The Children's Hospital of Zhejiang University...Not yet recruitingCongenital Heart Disease | Physical InactivityChina
-
Hartford HospitalNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)Recruiting
-
Selcuk UniversityThe Scientific and Technological Research Council of TurkeyCompletedSchizophrenia DisordersTurkey
-
Northumbria UniversityNewcastle-upon-Tyne Hospitals NHS TrustCompletedChronic Obstructive Pulmonary DiseaseUnited Kingdom
-
UKK InstituteFinnish Institute of Occupational Health; Finnish Sports Confederation; Päijät-Hämeen... and other collaboratorsCompletedPhysical Activity | Sedentary Behavior | Work AbilityFinland
-
University of North Carolina, Chapel HillNorth Carolina Translational and Clinical Sciences InstituteCompletedArthritis | Joint Diseases | Osteoarthritis | Osteoarthritis, Knee | Anterior Cruciate Ligament Injuries | Knee Injuries | Exercise | Cartilage, ArticularUnited States
-
University of PennsylvaniaRobert Wood Johnson FoundationCompleted
-
Medical College of WisconsinNational Cancer Institute (NCI)RecruitingCervical Cancer | Breast Cancer | Colorectal Cancer | Lung Cancer | Prostate Cancer | Bladder Cancer | Endometrial CancerUnited States